Shattuck Labs (STTK)
(Delayed Data from NSDQ)
$9.90 USD
+0.41 (4.32%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $9.87 -0.03 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.90 USD
+0.41 (4.32%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $9.87 -0.03 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 3.85% and 44.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 1,500% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -17.12% and 10.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 19.67% and 83.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Shattuck Labs, Inc. (STTK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Should You Buy Shattuck Labs (STTK) Ahead of Earnings?
by Zacks Equity Research
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Shattuck Labs (STTK)
by Zacks Equity Research
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.